The first clinical program to go over involves the use of ImmunityBio's CAR-NK cell therapy CD19 t-haNK, which is being tested in the ongoing phase 1 QUILT 106 study. As I alluded to above ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback